

Paul Andrew VanderLaan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857892/publications.pdf>

Version: 2024-02-01

139
papers

4,778
citations

117625

34
h-index

102487

66
g-index

141
all docs

141
docs citations

141
times ranked

6772
citing authors

#	ARTICLE	IF	CITATIONS
1	Pilot Gene Expression and Histopathologic Analysis of Tracheal Resections in Tracheobronchomalacia. <i>Annals of Thoracic Surgery</i> , 2022, 114, 1925-1932.	1.3	2
2	Molecular testing results as a quality metric for evaluating cytopathologists'™ utilization of the atypia of undetermined significance category for thyroid nodule fine-needle aspirations. <i>Journal of the American Society of Cytopathology</i> , 2022, 11, 67-73.	0.5	16
3	A frameshift error affecting multiple cytology cell blocks: Lessons from a near-miss event. <i>Cancer Cytopathology</i> , 2022, 130, 170-173.	2.4	1
4	Percutaneous Lung Biopsy: Point-of-Fine-Needle Aspiration First. <i>American Journal of Roentgenology</i> , 2022, 218, 794-795.	2.2	3
5	Pulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies. <i>Respiratory Medicine</i> , 2022, 191, 106697.	2.9	2
6	COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study. <i>Cancer Cytopathology</i> , 2022, 130, 344-351.	2.4	15
7	Reply to: Endobronchial Optical Coherence Tomography: Shining New Light on Diagnosing UIP?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	5.6	2
8	Pulmonary amyloidosis as the presenting finding in a patient with multiple myeloma. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101626.	0.4	1
9	All in for patient safety: a team approach to quality improvement in our laboratories. <i>Journal of the American Society of Cytopathology</i> , 2022, 11, 87-93.	0.5	3
10	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e379-e389.	2.6	13
11	The rapidly evolving landscape of biomarker testing in non-small cell lung cancer. <i>Cancer Cytopathology</i> , 2021, 129, 179-181.	2.4	13
12	Impact of a Modified HistoGel Method for Processing Endocervical Curettage Specimens on Diagnostic Yield. <i>American Journal of Clinical Pathology</i> , 2021, 155, 141-147.	0.7	2
13	Using the Model for Improvement and Plan-Do-Study-Act to effect SMART change and advance quality. <i>Cancer Cytopathology</i> , 2021, 129, 9-14.	2.4	0
14	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. <i>Oncologist</i> , 2021, 26, 281-287.	3.7	15
15	Argon Plasma Coagulation (APC) for the Treatment of Excessive Dynamic Airway Collapse (EDAC). <i>Journal of Bronchology and Interventional Pulmonology</i> , 2021, 28, 221-227.	1.4	2
16	A Case Report on Papillary Muscle Rupture Following Mitral Valve Replacement in the Setting of Previously Undiagnosed Amyloidosis. <i>A&A Practice</i> , 2021, 15, e01415.	0.4	0
17	Atypical histologic presentation of Pneumocystis pneumonia as granulomatous lung nodules. <i>Human Pathology: Case Reports</i> , 2021, 23, 200476.	0.2	1
18	Critical values in cytology. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 341-348.	0.5	2

#	ARTICLE	IF	CITATIONS
19	An Unusual Cause of Functional Mitral Stenosis. JACC: Case Reports, 2021, 3, 829-833.	0.6	1
20	Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance. Cancer Cytopathology, 2021, 129, 947-955.	2.4	10
21	Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1164-1179.	5.6	32
22	Vascular remodeling of the small pulmonary arteries and measures of vascular pruning on computed tomography. Pulmonary Circulation, 2021, 11, 1-9.	1.7	6
23	The impact of pathology grossing protocol measures to improve pathologic nodal staging in lung cancer. Cancer Treatment and Research Communications, 2021, 29, 100488.	1.7	1
24	A Man with Superior Vena Cava Syndrome and Granulomas. Annals of the American Thoracic Society, 2020, 17, 107-111.	3.2	1
25	Growth Assessment of Pulmonary Adenocarcinomas Manifesting as Subsolid Nodules on CT: Comparison of Diameter-Based and Volume Measurements. Academic Radiology, 2020, 27, 1385-1393.	2.5	9
26	Thermoablative Techniques for Excessive Central Airway Collapse. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 195-199.	1.4	4
27	A CASE OF FULMINANT CARDIAC SARCOIDOSIS RESEMBLING GIANT CELL MYOCARDITIS. Journal of the American College of Cardiology, 2020, 75, 2934.	2.8	0
28	The Growth Rate of Subsolid Lung Adenocarcinoma Nodules at Chest CT. Radiology, 2020, 297, 189-198.	7.3	14
29	Results from the 2019 American Society of Cytopathology survey on rapid onsite evaluation (ROSE)â€“part 2: subjective views among the cytopathology community. Journal of the American Society of Cytopathology, 2020, 9, 570-578.	0.5	11
30	CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in Ldlr ^{-/-} Mice. Antibodies, 2020, 9, 30.	2.5	3
31	Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	2.4	47
32	Current and future trends in nonâ€“small cell lung cancer biomarker testing: The American experience. Cancer Cytopathology, 2020, 128, 629-636.	2.4	18
33	Assessing invasiveness of subsolid lung adenocarcinomas with combined attenuation and geometric feature models. Scientific Reports, 2020, 10, 14585.	3.3	5
34	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2020, 1, 100051.	1.1	26
35	Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Archives of Pathology and Laboratory Medicine, 2020, 144, 933-958.	2.5	65
36	Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?., 2020, 8, e000697.		31

#	ARTICLE	IF	CITATIONS
37	Preoperative bronchial cytology for the assessment of tumor spread through air spaces in lung adenocarcinoma resection specimens. <i>Cancer Cytopathology</i> , 2020, 128, 278-286.	2.4	10
38	Role of imaging in predicting tumor spread through airspaces (STAS): what are the next steps. <i>Journal of Thoracic Disease</i> , 2020, 12, 1154-1156.	1.4	0
39	Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies Guideline from the College of American Pathologists (CAP): implications for the cytology community. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 286-290.	0.5	5
40	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e1-e3.	1.1	8
41	Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. <i>Cancer</i> , 2019, 125, 4164-4171.	4.1	30
42	ENDOSCOPIC ARGON PLASMA COAGULATION FOR EXCESSIVE CENTRAL AIRWAY COLLAPSE: AN EXPERIMENTAL PILOT ANIMAL STUDY. <i>Chest</i> , 2019, 156, A202-A203.	0.8	0
43	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1995-2002.	1.1	58
44	Visceral Pleural Invasion in Pulmonary Adenocarcinoma: Differences in CT Patterns between Solid and Subsolid Cancers. <i>Radiology: Cardiothoracic Imaging</i> , 2019, 1, e190071.	2.5	17
45	Yield of biliary stent cytology: Is it time to think lean?. <i>Endoscopy International Open</i> , 2019, 07, E545-E550.	1.8	4
46	Results from the 2019 American Society of Cytopathology survey on rapid on-site evaluation Part 1: objective practice patterns. <i>Journal of the American Society of Cytopathology</i> , 2019, 8, 333-341.	0.5	30
47	Invariant Natural Killer T-Cells and Total CD1d Restricted Cells Differentially Influence Lipid Metabolism and Atherosclerosis in Low Density Receptor Deficient Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4566.	4.1	5
48	Non-small cell lung cancer predictive biomarker testing via immunocytochemistry: Ways of future past?. <i>Cancer Cytopathology</i> , 2019, 127, 278-280.	2.4	5
49	The natural course of incidentally detected, small, subsolid lung nodules is follow-up needed beyond current guideline recommendations?. <i>Translational Lung Cancer Research</i> , 2019, 8, S412-S417.	2.8	3
50	False positive diagnosis of lymph node metastases in a 34-year-old woman with a history of extraskeletal myxoid chondrosarcoma: A root cause analysis. <i>Cancer Cytopathology</i> , 2019, 127, 69-71.	2.4	0
51	Repeat Contrast Medium Administration for Patients with Mild Immediate Hypersensitivity Reaction to Iodinated Contrast Media. <i>Radiology</i> , 2019, 290, 270-271.	7.3	1
52	CT Manifestations of Tumor Spread through Air Spaces in Lung Adenocarcinoma: Different Pathways toward Common Perspectives. <i>Radiology</i> , 2019, 290, 271-272.	7.3	6
53	Molecular Diagnostics in Lung Cytology. , 2019, , 223-247.		0
54	Comparison of plasma-thrombin, HistoGel, and CellGel cell block preparation methods with paired ThinPrep slides in the setting of mediastinal granulomatous disease. <i>Journal of the American Society of Cytopathology</i> , 2019, 8, 52-60.	0.5	7

#	ARTICLE	IF	CITATIONS
55	EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2019, 37, e20593-e20593.	1.6	3
56	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, e20617-e20617.	1.6	0
57	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-“small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. Journal of the American Society of Cytopathology, 2018, 7, 133-141.	0.5	56
58	Preoperative cytologic interpretation of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a 1-year multi-institutional experience. Journal of the American Society of Cytopathology, 2018, 7, 79-85.	0.5	15
59	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer, 2018, 116, 90-95.	2.0	46
60	Updated Correlation of 22C3-PD-L1 ~50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. Journal of Thoracic Oncology, 2018, 13, e81-e83.	1.1	0
61	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1037-1042.	1.1	83
62	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treatment and Research Communications, 2018, 15, 17-20.	1.7	10
63	Software-based risk stratification of pulmonary adenocarcinomas manifesting as pure ground glass nodules on computed tomography. European Radiology, 2018, 28, 235-242.	4.5	28
64	Pulmonary Sclerosing Pneumocytoma. Journal of Bronchology and Interventional Pulmonology, 2018, 25, e54-e56.	1.4	6
65	Pre-analytic error: A significant patient safety risk. Cancer Cytopathology, 2018, 126, 738-744.	2.4	19
66	CT Manifestations of Tumor Spread Through Airspaces in Pulmonary Adenocarcinomas Presenting as Subsolid Nodules. Journal of Thoracic Imaging, 2018, 33, 402-408.	1.5	43
67	Updates in Lung Cancer Cytopathology. Surgical Pathology Clinics, 2018, 11, 515-522.	1.7	4
68	Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5963-5976.	7.0	63
69	Histopathological Demonstration of Subacute Endothelialization Following Aneurysm Retreatment with the Pipeline Embolization Device. World Neurosurgery, 2018, 118, 156-160.	1.3	6
70	Molecular Testing Turnaround Time in Non-“Small-Cell Lung Cancer: Monitoring a Moving Target. Clinical Lung Cancer, 2018, 19, e589-e590.	2.6	13
71	Pathologic T Descriptor of Nonmucinous Lung Adenocarcinomas Now Based on Invasive Tumor Size. American Journal of Clinical Pathology, 2018, 150, 499-506.	0.7	9
72	Lymphangioleiomyomatosis. New England Journal of Medicine, 2018, 378, 2224-2224.	27.0	6

#	ARTICLE	IF	CITATIONS
73	Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9069-9069.	1.6	7
74	Suspicious for Malignancy. , 2018, , 101-118.		2
75	Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer, 2017, 106, 17-21.	2.0	149
76	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3â€“PD-L1 â‰¥50% Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, 878-883.	1.1	109
77	P1.02-031 Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes. Journal of Thoracic Oncology, 2017, 12, S506.	1.1	1
78	Implementation of the Paris System for Reporting Urinary Cytology results in lower atypical diagnostic rates. Journal of the American Society of Cytopathology, 2017, 6, 205-210.	0.5	22
79	Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. Journal of Thoracic Oncology, 2017, 12, 1288-1298.	1.1	75
80	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. Journal of Thoracic Oncology, 2017, 12, e175-e177.	1.1	15
81	Measurement Bias of Gross Pathologic Compared With Radiologic Tumor Size of Resected Lung Adenocarcinomas. American Journal of Clinical Pathology, 2017, 147, 641-648.	0.7	20
82	Molecular Testing Turnaround Time for Nonâ€“Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clinical Lung Cancer, 2017, 18, e349-e356.	2.6	31
83	Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules â‰¥30â‰“mm on CT. Academic Radiology, 2017, 24, 851-859.	2.5	26
84	De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer, 2017, 114, 108-110.	2.0	9
85	Measuring and assuring quality performance in cytology: A toolkit. Cancer Cytopathology, 2017, 125, 502-507.	2.4	20
86	â€œRoundingâ€“the Size of Pulmonary Nodules. Academic Radiology, 2017, 24, 1422-1427.	2.5	12
87	Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. Journal of Thoracic Disease, 2017, 9, E1148-E1150.	1.4	2
88	Fineâ€“needle aspiration and core needle biopsy: An update on 2 common minimally invasive tissue sampling modalities. Cancer Cytopathology, 2016, 124, 862-870.	2.4	71
89	Pulmonary Cyst of Uterine Genesis. Chest, 2016, 150, 649A.	0.8	0
90	Osseous and chondromatous metaplasia in calcific aortic valve stenosis. Cardiovascular Pathology, 2016, 25, 18-24.	1.6	37

#	ARTICLE	IF	CITATIONS
91	Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. <i>Clinical Lung Cancer</i> , 2016, 17, e169-e172.	2.6	0
92	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. <i>Diagnostic Cytopathology</i> , 2016, 44, 1000-1009.	1.0	55
93	Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 41-43.	1.7	7
94	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. <i>Lung Cancer</i> , 2016, 99, 17-22.	2.0	16
95	Thymic carcinoma with brain metastases: A rare presentation of a rare malignancy. <i>Cancer Treatment Communications</i> , 2016, 7, 21-22.	0.4	0
96	EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. <i>Clinical Lung Cancer</i> , 2016, 17, 483-492.	2.6	52
97	Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 498-507.	1.7	15
98	Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice. <i>Cancer Treatment Communications</i> , 2015, 4, 174-181.	0.4	24
99	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015, 6, 6377.	12.8	498
100	Extended distance transmission over wideband MMF using multi-wavelength VCSEL based transceivers. , 2015, , .		0
101	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015, 88, 108-111.	2.0	369
102	Cytologic rapid on-site evaluation of transthoracic computed tomography-guided lung needle biopsies: who should perform ROSE? A cross-institutional analysis of procedural and diagnostic outcomes. <i>Journal of the American Society of Cytopathology</i> , 2015, 4, 160-169.	0.5	9
103	De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. <i>Lung Cancer</i> , 2015, 88, 70-73.	2.0	30
104	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. <i>Clinical Lung Cancer</i> , 2015, 16, 334-339.e1.	2.6	28
105	Molecular markers: Implications for cytopathology and specimen collection. <i>Cancer Cytopathology</i> , 2015, 123, 454-460.	2.4	30
106	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. <i>Clinical Lung Cancer</i> , 2015, 16, e105-e109.	2.6	10
107	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015, 90, 369-374.	2.0	70
108	CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0120647.	2.5	6

#	ARTICLE	IF	CITATIONS
109	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 392-403.	2.8	24
110	Adequacy of Pleural Fluid Cytology and Pleural Biopsies for Multiple Tumor Genotyping Techniques in Non-small Cell Lung Cancer. <i>Chest</i> , 2014, 146, 609A.	0.8	1
111	A Case of Hypercalcemia Secondary to Hot Tub Lung. <i>Chest</i> , 2014, 146, e186-e189.	0.8	4
112	A 50-Year-Old Man with Cirrhosis and Progressive Hypoxemia. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1149-1151.	3.2	0
113	Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy. <i>Laryngoscope</i> , 2014, 124, 188-195.	2.0	147
114	Pill Aspiration Presenting as an Endobronchial Tumor. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2014, 21, 162-165.	1.4	5
115	Recovery of giant-cell myocarditis using combined cytolytic immunosuppression and mechanical circulatory support. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 769-771.	0.6	11
116	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. <i>Lung Cancer</i> , 2014, 84, 39-44.	2.0	135
117	Endobronchial ultrasoundâ€guided transbronchial needle aspiration (EBUSâ€TBNA): An overview and update for the cytopathologist. <i>Cancer Cytopathology</i> , 2014, 122, 561-576.	2.4	86
118	EBUS-TBNA of Pulmonary Artery Clot. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2014, 21, 371-373.	1.4	2
119	Head and Neck: Thyroid. , 2014, , 123-159.		0
120	6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met. <i>Biochemical and Biophysical Research Communications</i> , 2013, 439, 247-251.	2.1	42
121	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. <i>Lung Cancer</i> , 2013, 82, 31-37.	2.0	48
122	A microthymoma and no germinal centre in myasthenia gravis. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 44, 1146-1147.	1.4	2
123	Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Nonâ€Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, e23-e24.	1.1	23
124	Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Nonâ€Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1438-1444.	1.1	71
125	Use of Lymph Node Aspirates From Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 144, 813A.	0.8	0
126	Practical Approach to the Evaluation of Prosthetic Mechanical and Tissue Replacement Heart Valves. <i>Surgical Pathology Clinics</i> , 2012, 5, 353-369.	1.7	5

#	ARTICLE	IF	CITATIONS
127	The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio. Cancer Cytopathology, 2012, 120, 111-116.	2.4	119
128	Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. Cancer Cytopathology, 2012, 120, 245-253.	2.4	56
129	Atypia of Undetermined Significance and Nondiagnostic Rates in The Bethesda System for Reporting Thyroid Cytopathology Are Inversely Related. American Journal of Clinical Pathology, 2012, 137, 462-465.	0.7	35
130	Clinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations. American Journal of Clinical Pathology, 2011, 135, 770-775.	0.7	197
131	Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thrombosis and Haemostasis, 2011, 106, 814-819.	3.4	33
132	Usefulness of Diagnostic Qualifiers for Thyroid Fine-Needle Aspirations With Atypia of Undetermined Significance. American Journal of Clinical Pathology, 2011, 136, 572-577.	0.7	102
133	The Frequency of "Atypia of Undetermined Significance"™ Interpretations for Thyroid Fine-Needle Aspirations Is Negatively Correlated with Histologically Proven Malignant Outcomes. Acta Cytologica, 2011, 55, 512-517.	1.3	57
134	Repeatedly Nondiagnostic Thyroid Fine-Needle Aspirations Do Not Modify Malignancy Risk. Acta Cytologica, 2011, 55, 539-543.	1.3	20
135	VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. Journal of Lipid Research, 2009, 50, 376-385.	4.2	69
136	The Immune System and Murine Atherosclerosis. Current Drug Targets, 2007, 8, 1297-1306.	2.1	10
137	Characterization of the Natural Killer T-Cell Response in an Adoptive Transfer Model of Atherosclerosis. American Journal of Pathology, 2007, 170, 1100-1107.	3.8	71
138	Thematic review series: The Immune System and Atherogenesis. The unusual suspects:an overview ofthe minor leukocyte populations in atherosclerosis. Journal of Lipid Research, 2005, 46, 829-838.	4.2	89
139	Site Specificity of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 12-22.	2.4	509